Shares of Regeneron Pharmaceuticals Inc. slipped 3.63% to $527.78 Friday, on what proved to be an all-around poor trading ...

We recently compiled a list of the 10 Jim Cramer Stocks with Huge Upside Potential. In this article, we are going to take a ...

Despite a risk for severe side effects, pembrolizumab has a record of improving recurrence-free survival that makes it an appealing treatment for advanced melanoma.

Regeneron Pharmaceuticals Inc. closed 54.78% below its 52-week high of $1,211.20, which the company reached on August 27th.

Four Gatton Academy of Mathematics and Science students presented their research at the Louisville Regional Science and ...

We recently published a list of Billionaire Mario Gabelli’s 10 Large-Cap Stock Picks with Huge Upside Potential. In this ...

Learn more about whether Alnylam Pharmaceuticals, Inc. or Exact Sciences Corporation is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

Schonfeld Strategic Advisors made a bold biotech play by boosting its Regeneron holdings by over 475% in Q4. The firm added ...

Shares of Regeneron Pharmaceuticals Inc. REGN rallied 2.65% to $605.61 Friday, on what proved to be an all-around favorable ...

We recently published an article titled Jim Cramer Listed 20 Best Performing Stocks of the Last 20 Years. In this article, we ...

Robert Radick writes his first health care enforcement roundup column for the NYLJ. "This new column will, every two months, ...

MML Investors Services ramped up its Regeneron stake by 41.7%, acquiring 2,218 additional shares during Q4. This brings their ...